- Home
- LU vs IOVA Comparison
LU vs IOVA Comparison
Compare LU & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LU | IOVA |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2020 | 2008 |
Fundamental Metrics
Financial Performance| Metric | LU | IOVA |
|---|---|---|
| Price | $1.42 | $4.22 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $2.00 | ★ $9.00 |
| AVG Volume (30 Days) | 1.5M | ★ 13.4M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $47.74 |
| Revenue Next Year | $22.52 | $40.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.20 | $1.70 |
| 52 Week High | $4.57 | $5.63 |
Technical Indicators
Market Signals| Indicator | LU | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 48.55 | 54.43 |
| Support Level | $1.29 | $2.07 |
| Resistance Level | $2.77 | $4.35 |
| Average True Range (ATR) | 0.07 | 0.33 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 89.80 | 45.90 |
Price Performance
Historical ComparisonAbout LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is an investment holding company, together with its consolidated subsidiaries, engaged in core retail credit and enablement business to both borrowers and institutions in the People's Republic of China. The group's segments are Lending-related business, which provides Retail credit and enablement, consumer finance loans, and Digital banking business, including Retail banking and SME banking.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.